Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

2.600 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 2.600
Bid (Size) 2.010 (100)
Ask (Size) 3.000 (3,000)
Prev. Close 2.600
Today's Range 2.600 - 2.600
52wk Range 1.350 - 3.580
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
From Chemomab Therapeutics Ltd.
Via GlobeNewswire

Performance

YTD
+45.3%
+45.3%
1 Month
+36.8%
+36.8%
3 Month
+46.1%
+46.1%
6 Month
+39.8%
+39.8%
1 Year
-13.0%
-13.0%

More News

Read More
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
11 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces New Medical and Clinical Appointments
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease ↗
Via Benzinga
News headline image
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
From Chemomab Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Chemomab Therapeutics Ltd. - American Depositary Shares publicly traded?
Yes, Chemomab Therapeutics Ltd. - American Depositary Shares is publicly traded.
What exchange does Chemomab Therapeutics Ltd. - American Depositary Shares trade on?
Chemomab Therapeutics Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares?
The ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares is CMMB on the Nasdaq Stock Market
What is the current price of Chemomab Therapeutics Ltd. - American Depositary Shares?
The current price of Chemomab Therapeutics Ltd. - American Depositary Shares is 2.600
When was Chemomab Therapeutics Ltd. - American Depositary Shares last traded?
The last trade of Chemomab Therapeutics Ltd. - American Depositary Shares was at 09/10/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.